The Change Of The CD4~+CD25~+T Cells Expressed In Peripheral Blood Between Early Period And Remission Sle Patients

Objective:Systemic lupus erythematosus (SLE) is a kind of typical dueto their own immune regulating function disorder which leads to multipleorgan damage in autoimmune diseases. T cell dysfunction plays a key role inthe initiation of immune abnormalities process. At present CD4~+CD25~+Tcells is the the hot topics in the research.CD4~+CD25~+T cells mainly comes from the thymus cells, produces in theprocess of natural selection of CD4+Tcell, accounting for about10%of thefine CD4+T. CD4~+CD25~+T cells is a kind of immune regulation cells, the mainplay an immune adjustment function, In maintaining the stability of theenvironment, in the Anti-infection immune, antitumor immunity, induceTransplantation tolerance autoimmune diseases, etc, Play an important role.Study found that the inflammatory response in immune tissue can rapid andeffective gathered to this organization generation activate cells to suppressbecause inflammation of its own response CD4~+CD25~+T cells and CD8+Tcells, immune suppression to play the role.At present CD4~+CD25~+Treg cells have been human widely used inclinical treatment From two aspects to treat disease:First, through theincrease of regulatory T cells active treatment autoimmune diseases and graftrejection. Second, by reducing the activity of regulatory T cells to treat tumorimmunity and specific vaccine inoculation. Current treatments of systemiclupus erythematosus drug is mainly adrenal cortical hormone and sugarimmunosuppressive agents. Study found that adrenal cortical hormone sugarcan transcriptional regulation in patients with the structure of thechromosome. Thus inducing inhibition gene expression rate through theFoxp3dependent mechanism of promoting T cell to Tr1direction ofdifferentiation, the immune response to immune suppression. research shows, dexamethasone can increase the number of CD4~+CD25~+T cells Tregs inlymphoid organs, this is because the CD4~+CD25~+Tregs high expression ofthe glucocorticoid receptor.At present about CD4~+CD25~+Treg in patients with systemic lupuserythematosus of the pathogenesis and drug treatment of the size of theinfluence of the report is not the same. This study through detect new-onsetand remission SLE patients in peripheral blood CD4~+CD25~+Tcells expresschanges, To further explore the pathogenesis of systemic lupus erythematosusand adrenal glucocorticoid and immune suppression influence to CD4+CD25+T cells. For the treatment of systemic lupus erythematosus provides anew approach.Method:1We selected48cases of systemic lupus erythematosus patients assubjects, divided into2groups:（1）SLE early group24cases（2）SLEremission group24cases2Application of flow cytometry assay for detection of two groups ofCD4~+CD25~+Tcell%, Ou Meng spot test for the anti-dsDNA antibody,indirect immunofluorescence analysis of detecting an tinuclearan tibody(ANA). Contemporary records of patients with clinical manifest tations(including fever, rash, arthritis, alopecia, oralulcer, central nervous systemdamage), laboratory tests (including blood routine, urine routine and stoolroutine, erythrocyte sedimentation rate, complement, antinuclear antibody,anti-dsDNA antibody, anti-Sm antibody,, the heart color, color Dopplerultrasound, abdominal pulmonary CT), disease activity score.3Statistical data processing: The study of measurement data withx±susing test; the correlation between variables using Spearman correlationanalysis. P <0.05there is a significant difference.Results:1The percentage of CD4~+CD25~+T cell in new-onset of systemic lupuserythematosus group higher than remission group2The percentage of CD4~+CD25~+T cell in kidney damage and no kidney damage has no significant differences3SLEDAI scores and the percentage of CD4~+CD25~+Tcell are notsignificantly correlation.4Systemic lupus erythematosus patients inremission group cyclophos-phamide accumulation and CD4~+CD25~+T cell number was not significantlycorrelation.Conclusions:1The percentage of CD4~+CD25~+T cell in new-onset of systemic lupuserythematosus group higher than remission group. CD4~+CD25~+T cells May beinvolved in the morbidity process.2The percentage of CD4~+CD25~+T cells in kidney damage and no kidneydamage has no differences.3SLEDAI scores and the percentage of CD4~+CD25~+T cells are notsignificantly correlation.4Glucocorticoid combined with cyclophosphamide can reduce thepercentage of CD4~+CD25~+T cells of SLE patients.5The percentage of CD4~+CD25~+T cell was not correlated with cyclopho-sphamide cumulant.